Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, ...

The approach requires balance, however. There is the risk of increased AEs, as well as financial toxicity. Friedlander shared ...

Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...

Bladder cancer occurs when cancerous cells form in the tissues of the bladder, the hollow organ in your abdomen that stores urine. The bladder has several layers, and cancer cells can form in any ...

Bladder cancer is the most common malignant tumor of the urinary system. We investigated the clinical implications of cell lineages in bladder cancer by integrating single-cell and bulk transcriptome ...

Figure 1 The graphical abstract of analyses performed in this study 1) Urine samples of healthy individuals and different types of bladder cancer patients (primary, recurrent and non-recurrent cohorts ...

Coping with bladder cancer after treatment includes follow up surveillance to identify signs of recurrence. What causes bladder cancer? Bladder cancer occurs when cells in the bladder mutate (their ...

The proteomic landscape of muscle-invasive bladder cancer (MIBC) in the context of platinum-based neoadjuvant chemotherapy (NAC) remains to be explored. Here, proteomic analysis of MIBC tumours ...

Neuropathy, skin rash, and hyperglycemia following enfortumab vedotin treatment were associated with improved PFS in ...